PARIS, June 11, 2009 -- Biosystems International (BSI) a biotechnology company focused on the development of novel monoclonal antibody-based diagnostics for cancer and metabolic diseases has established a licensing agreement with the Lohocla Research Corporation for the use of BSI’s patented monoclonal antibody proteomics platform for the discovery of novel alcoholism liver disease biomarkers in blood. Terms of the agreement were not disclosed.
About Alcoholism and Liver Disease
Alcohol-use disorder includes both alcohol abuse and alcohol dependence. Both contribute to one of society’s most expensive, destructive, and tragic problems. Alcohol-use disorder afflicts 17.6 million individuals in the U.S. and costs $185 billion in direct and indirect expenses yearly. Alcohol abuse kills at least 75,000 Americans each year and decreases longevity by an average of thirty years. Heavy alcohol consumption often leads to alcohol induced liver disease including fatty liver and hepatitis. Currently, definitive diagnosis of this condition requires analysis by biopsy, usually when symptoms are already apparent and liver damage may be extensive. “A non-invasive blood test for the early detection of alcohol induced liver disease would identify those at risk and encourage abstinence from alcohol resulting in lower mortality due to a lower prevalence of advanced liver disease as well as other alcohol related health problems,” stated Boris Tabakoff, President and CEO of Lohocla. “This agreement provides BSI with another opportunity to apply our powerful technology in an area where there is a critical unmet medical need,” added Jean-Pierre Tirouflet, CEO of Biosystems International.
About Biosystems International
Biosystems International (BSI) is a biotechnology company aiming to become a world leader in the discovery and development of novel diagnostics for diseases with critical unmet needs. Using our proprietary monoclonal antibody proteomics process BSI rapidly discovers novel biomarkers and corresponding antibodies in a single step. The company is currently focused on the discovery and development of diagnostic tests in the areas of cancer and metabolic diseases as well as the development and commercialization of antibody arrays for plasma proteome profiling.
About Lohocla
Lohocla is a research and development company that is at the forefront of discovery of medications for addictive and other mental health and neurological disorders. Lohocla is unique in its dedication to developing biological markers (diagnostics) that aid the physician properly to allocate Lohocla-developed CNS medications to the appropriate patients. The tenets of personalized medicine drive the company’s research efforts.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the company assumes no responsibility to update any such forward looking statements.
Contact:
Biosystems International
Laszlo Takacs, M.D., Ph.D, D.Sc.
CSO and General Director
+33 (0)1 60 87 89 75
info@biosys-intl.com
Lohocla
Boris Tabakoff, Ph.D.
President and CEO
720 859 4083
inquiry@lohocla.com